Cardiovascular disease continues to pose a major global health burden. At the same time, breakthroughs in technology and research are offering promising new avenues for prevention, diagnosis, and treatment. But how do we ensure these innovations actually reach patients and make a difference in real-world care?
This session brings together diverse perspectives – from fundamental science and clinical expertise to entrepreneurial ventures – to explore how cardiovascular technologies can be successfully translated into practice. Through concrete case studies and expert insights, we’ll examine how engineered heart models and computational simulations are reshaping drug development, deepening our understanding of disease mechanisms, and enabling earlier detection.
We'll also hear from emerging companies about the journey from university lab to scalable business, and from clinicians and translational researchers on integrating innovation into care pathways and training programmes. Ultimately, this session invites an open conversation around a core challenge: how do we design cardiovascular technologies that are not only scientifically groundbreaking but also feasible, adoptable, and truly meaningful for patients and healthcare systems?
The planning
Time | Content |
|---|---|
10.45 - 10.50 | Setting the sceneAn introduction by the moderator, linking today’s theme to earlier insights and setting the stage for the speakers to come. |
10.50 - 11.05 | Shaping the future of cardiovascular health technologyRobert Passier, University of Twente |
11.05 - 11.20 | Leveraging 3D cardiac models for drug discoveryMarcelo Ribeiro, River Biomedics |
11.20 - 11.35 | Patient-centred design of a soft robotic total artificial heartWouter Weijermars, Saxion University of Applied Sciences |
11.35 - 11.50 | The heart of medical innovationMireille Post-Hubers, University of Twente |
11.55 - 12.00 | From insights to action: closing reflectionsRobert Passier, University of Twente & Medisch Spectrum Twente |
Confirmed speakers
|
|
|
|
